VKTX
R500#20 today
$26.77
+5.10% today · -3.46% 1W
Oct 15 close or latest
ReadoutWhy it's moving
Moving with its weight-loss drugs peers
- VKTX +5.10% on the last session vs SPY −0.00%: +5.1 pts of stock-specific move.
- Weight-loss drugs basket +4.6% (+4.5 pts vs SPY; LLY +5.3%, NVO +3.8%): the stock moved with its peers.
- Market backdrop (Today): Core PPI m/m 1.3% vs 0.3% expected (hotter); Core Retail Sales m/m 0.9% vs 0.6% expected (stronger); S&P futures -0.08%, 10-year yield -3bp in the 30 minutes after.
Assembled from Wallsti's own signals.
Activity & positioning
- Volume
- 0.6× its 20-day averagepace so far
- Short interest
- —
- Options volume
- —
- Implied volatility
- —
- Options-implied move
- —
Moved with
Headlines
No headlines for VKTX yet.
Weight-loss drugs · theme headlines
- QUICK SPARK: This New ETF Goes Beyond Eli Lilly, Novo Nordisk and Targets the Peptide Boom
- Roche Expands Obesity Pipeline With Rona's RNAi Candidate
- Novo Nordisk A/S (NOVO-B.CO) stock price, news, quote and history - Yahoo Finance
- Viking’s Key Obesity Pill Enters Phase 3 Trial – Here’s What Investors Need To Know
- Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), Intuitive Surgical (NASDAQ: ISRG), And Medtronic (NYSE: MDT) Stand Out As Long-Term Healthcare Plays
- FDA approves Eli Lilly’s weight-loss pill; Judge revokes citizenship over stolen medical secrets for China; new COVID-19 ‘Cicada’ variant spreads to 25 states – Morning Medical Update
Fetched hourly from Yahoo Finance (the stock) and Google News (its themes). ✦ marks the headline an AI-read catalyst cited.
Key facts
- Market cap
- —
- Held by institutions
- —
- 52-week range
- —
- Analyst mean target
- —
- Next earnings
- Oct 28 est.
- Forward P/E
- —